Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$120,000.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
W81XWH-10-C-0005
Agency Tracking Number:
A092-107-1383
Solicitation Year:
2009
Solicitation Topic Code:
A09-107
Solicitation Number:
2009.2
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100, Ithaca, NY, 14850
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
N
Duns:
022552900
Principal Investigator:
Mehran Pazirandeh
Staff Scientist
(607) 272-0002
mehranp@agavebio.com
Business Contact:
Noe Salazar
President
(512) 656-6200
nsalazar@agavebio.com
Research Institution:
n/a
Abstract
Development of an effective malarial vaccine has been slow, although recent success in vaccine development has been achieved by using the Plasmodium falciparum circumsporozoite surface protein (CSP)-hepatitis B surface antigen fusions, in conjunction with hepatitis B particles (the RTS, S formulation). The results of these studies suggest the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems proposes to develop a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The NV-VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government